Spotlight On... inVentiv opens new Phase I clinic; Pfizer taps Adaptive for immunotherapy R&D; and much more...

CRO inVentiv Health is expanding its early-stage research capabilities, opening a new Phase I clinic in Florida. The facility, sited at the University of Miami Life Science and Technology Park, has room for 44 beds, complementing inVentiv's existing Phase I-IV services around the U.S., the company said. More

> Pfizer ($PFE) signed a deal with Adaptive Biotechnologies to use the company's genomic sequencing technology in its efforts to develop immuno-oncology therapies. News

> The Indian CRO market has plenty of room to grow, according to the departing CEO of Biocon's Syngene. Story

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.